A Study to Assess the Safety, Pharmacokinetics, and Activity of RO7790121 in Participants With Advanced MASH Liver Fibrosis

Exclusion Criteria

• •Weight gain or loss \>5% in the 3 months prior to baseline or \>10% in the 6 months prior to baseline
• •Bariatric surgery within 1 year prior to baseline
• •Current signs or prior history of decompensated liver disease
• •Complications or clinical evidence of portal hypertension
• •Lack of peripheral venous access
• •Other causes of liver disease based on medical history and/or centralized review of liver histology
• •History of liver transplantation
• •Current or prior history of hepatocellular carcinoma (HCC)
• •Uncontrolled hypertension
• •Concomitant Type 1 diabetes, or Type 2 diabetes with HbA1c \>10%
• •History of malignancy within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death
• •Current, significant alcohol consumption or a history of significant alcohol consumption for a period of more than 3 consecutive months any time within 1 year prior to screening
• •Initiation of a medication of an antidiabetic, weight loss, lipid-modifying or anti-depressant drug class
• •Active tuberculosis requiring treatment within the 12 months prior to baseline
• •History of organ transplant